Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Consensus Price Target of $22.43

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $22.00.

A number of equities research analysts recently weighed in on ARCT shares. BTIG Research lowered their price target on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, September 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. Citigroup upgraded shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $8.00 to $20.00 in a report on Thursday, September 24th. Leerink Partners boosted their price objective on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Wall Street Zen cut shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARCT. Green Alpha Advisors LLC lifted its stake in shares of Arcturus Therapeutics by 7.9% in the third quarter. Green Alpha Advisors LLC now owns 29,234 shares of the biotechnology company’s stock worth $400,000 after acquiring an additional 2,143 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Arcturus Therapeutics by 648.6% in the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 2,627 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Arcturus Therapeutics by 264.8% in the second quarter. Squarepoint Ops LLC now owns 50,253 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 36,479 shares during the last quarter. Corient Private Wealth LP purchased a new position in Arcturus Therapeutics in the second quarter valued at about $117,000. Finally, Two Sigma Securities LLC acquired a new stake in Arcturus Therapeutics during the 2nd quarter valued at approximately $80,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Stock Up 6.8%

Shares of NASDAQ:ARCT opened at $13.74 on Tuesday. Arcturus Therapeutics has a 52-week low of $5.50 and a 52-week high of $24.17. The company has a 50 day moving average of $12.75 and a two-hundred day moving average of $9.29. The company has a market capitalization of $390.49 million, a price-to-earnings ratio of -4.15 and a beta of 2.48.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. On average, equities analysts anticipate that Arcturus Therapeutics will post -3.48 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need.